EN DE
Watch Zai Lab Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zai Lab Ltd (9688) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Zai Lab Ltd stock HK$16.10, price HK$19.18, that is 16.1% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG9887T1168

ZL Zai Lab Ltd logo Thin data Nov 11, 2026

Zai Lab Ltd

9688 · HK

Expensive (fair value 16% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Quality 48/100 
Price moving sideways (no uptrend) 
Mixed Growth (revenue 5y +56.6 %/yr in USD) 
Fair value HK$16.10 · Overvalued 
Loss-making · -44.9% net margin (TTM) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Zai Lab Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$136.50 HK$10.62 Fair Value HK$16.10 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range HK$10.62 – HK$136.50 · fair‑value band HK$12.07 – HK$20.12 · the HK$19.18 price screens above the HK$16.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Zai Lab in your weekly email

Every Wednesday you see whether Zai Lab is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

Show moreShow less

Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Stock analysis

Zai Lab Ltd (9688) currently trades at HK$19.18, while our estimate is HK$16.10, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$12.07 (bear) to HK$20.12 (bull), the price of HK$19.18 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Zai Lab Ltd reported revenue of $461M in FY2025 versus $144M in FY2021, a compound +33.7%/yr. Reported net income was −$176M in FY2025.

Key figures

Market cap HK$24.9B (≈ $3.2B) Mid · P/S ratio 60.2 · EPS (TTM) HK$−0.1900 · Net margin −38.1% · Return on equity −30.0% · Return on assets (EBIT) −31.1% (5-year average) · Operating margin −58.2% · Revenue (TTM) $442M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 54% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −16%, 9688 screens richer than that median.

Fair Value

Bear HK$12.07 Fair Value HK$16.10 Bull HK$20.12
Price HK$19.18 · Downside -16.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 53
Distance to the 52-week high, does not count
New shares 30
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+221.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−616.4% (2020) → −49.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

9688 screens overvalued: fair value 16% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Zai Lab Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Above median
Fair Value upside −16.1% · Above median
Profitability
Return on assets −15.0% · Above median
Net margin (12 months) −44.9% · Below median
Operating margin (12 months) −58.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −6.8% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.44× · Pricier than median
P/S (12 months) 7.19× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 9688
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 9688
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 9688
argenx SE ARGX $950.95 $908.40 −4% vs 9688
CSL Limited CSL A$202.52 A$186.49 −8% vs 9688
Moderna, Inc MRNA $215.27 $135.64 −37% vs 9688
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 9688
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 9688
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 9688
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 9688

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zai Lab Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zai Lab Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9688

Frequently asked questions

Is Zai Lab Ltd (9688) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is HK$16.10 versus a price of HK$19.18, about 16% lower (overvalued).
What is the fair value of 9688?
Our estimate for Zai Lab Ltd is HK$16.10 (as of Nov 11, 2026), built from audited fundamentals. The current price: HK$19.18.
What is the quality score of 9688?
Zai Lab Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zai Lab Ltd (9688)?
Our calculated price target is the estimate of HK$16.10 (as of Nov 11, 2026). Cautious scenario HK$12.07, optimistic scenario HK$20.12. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Zai Lab Ltd stock forecast for 2026?
Our estimate puts fair value at HK$16.10, about 16% lower versus a price of HK$19.18 (overvalued). Cautious scenario HK$12.07, optimistic scenario HK$20.12. The calculation is refreshed regularly with new filings.
What is the revenue of Zai Lab Ltd (9688)?
Zai Lab Ltd reported trailing-twelve-month revenue of about $442M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Zai Lab Ltd (9688)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zai Lab Ltd it is HK$16.10 per share (as of Nov 11, 2026), against a price of HK$19.18.
Is Zai Lab Ltd stock overvalued or undervalued in 2026?
As of Nov 11, 2026, 9688 trades above its calculated fair value: price HK$19.18, fair value HK$16.10, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9688?
No. The price is what the market pays today (HK$19.18); the fair value is what the company's own numbers justify (HK$16.10). For Zai Lab Ltd the two are HK$3.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zai Lab Ltd worth?
The market values Zai Lab Ltd at about HK$24.9B (market capitalisation, as of Nov 11, 2026). Per share that is HK$19.18; our models calculate a fair value of HK$16.10 per share.
What do the bullish and bearish scenarios say about 9688?
Our models span a range for Zai Lab Ltd: cautious scenario HK$12.07, base HK$16.10, optimistic HK$20.12 per share (as of Nov 11, 2026, price HK$19.18). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zai Lab Ltd (9688)?
Balance-sheet figures for Zai Lab Ltd (as of Nov 11, 2026): return on equity −30.0%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 9688 from its 52-week high?
Zai Lab Ltd trades at HK$19.18, about 11% below its 52-week high of HK$21.48 and 54% above the low of HK$12.44 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of HK$16.10 is for.
Which stocks are comparable to Zai Lab Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zai Lab Ltd stock attractive at the current price?
The data as of Nov 11, 2026: price HK$19.18, calculated fair value HK$16.10 (−16%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Zai Lab Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zai Lab Ltd (9688)?
The closing price on Nov 16, 2026 was HK$19.18. Our estimate is HK$16.10, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zai Lab Ltd right now?
Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Zai Lab Ltd

How large is the market capitalisation of Zai Lab Ltd (9688)?
The market capitalisation of Zai Lab Ltd is HK$24.9B (≈ $3.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zai Lab Ltd (9688)?
The price-to-sales ratio of Zai Lab Ltd is 60.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zai Lab Ltd (9688)?
Earnings per share at Zai Lab Ltd are HK$−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zai Lab Ltd (9688)?
The net margin of Zai Lab Ltd is −38.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zai Lab Ltd (9688)?
The return on equity (ROE) of Zai Lab Ltd is −30.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zai Lab Ltd (9688)?
On an EBIT basis the return on assets of Zai Lab Ltd is −31.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zai Lab Ltd (9688)?
The operating margin of Zai Lab Ltd is −58.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zai Lab Ltd (9688)?
Revenue at Zai Lab Ltd is down 6.8% versus a year earlier (3y avg +28.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Zai Lab Ltd (9688) generate?
The free cash flow of Zai Lab Ltd is −$159M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Zai Lab Ltd (9688) hold?
Zai Lab Ltd holds more cash than debt, $455M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Zai Lab Ltd in the live analysis

One click puts Zai Lab Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.